In Jun 2022, licensed in three products from Italy NTC S.r.l
In May 2022, entered into a strategic partnership with Aosaikang
In Mar 2022, achieved Series B /B+ Round financing with nearly 100 of millions RMB
In Mar 2022, licensed in one product from Netherlands Synthon B.V.
In Feb 2022. licensed in one product from Dr Reddy’s.
In Nov 2021, started co-development with MedPharm for a drug in global new dosage form
In Oct 2021, started co-development with LTS for a drug in global new dosage form
In Oct 2021, Oselavir® (Oseltamivir Phosphate for Suspension) has received regulatory approval
In Sep 2021, licensed in another one product from Cipla
On 26th January 2021, Shenzhen Beimei Pharma completed A round financing
In December 2020, Beimei Pharma and Deva Holding A.Ş. reached an exclusive license and supply agreement in China for one product that have been approved for marketing in European
In October 2020, Beimei Pharma and Cipla reached an exclusive license and supply agreementin China for two products that have been approved for marketing in the United States
In September 2020, Beimei Pharma and EMP Pharma reached an exclusive license and supply agreement for an innovative oral solution in China
In June 2020, the company's imported Lacosamide Oral Solution was officially accepted by NMPA and has entered the review stage.
In Apr. 2020, started the development of BMR05BK
On April 23, 2020, Beimei R&D center for pediatric medicines was officially put into use.
In December 2019, the company's imported Oseltamivir Phosphate for Oral Suspension was officially accepted by NMPA and has entered the review stage.
In June 2019, Signed a license and supply agreement with Hetero of India on four FDA-approved prescription drugs for children, an exclusive license to register and commercialize the products in the territory for at lease 10 years. And it is expected that the total sales scale of the four products will reach more than 800 million yuan.
In March 2019: Individual investor completed an angel investment with the amount of 10 million yuan.
In February 2019: Signed a license and supply agreement with Workhardt in India on anti epileptic drugs approved by FDA, which is an exclusive license to register and commercialize the product in the territory for at lease 10 years.
In June 2018: Establishment of Shenzhen Beimei Enterprise Management Co., Ltd. as the employee shareholding platform, accounting for 15% of the equity of Beimei Pharma.
In March 2018: Invested in R & D BM_R03_TM and cooperated with a R & D institution in Guangzhou.
In January 2018: Invested in R & D BM_R01_DL and cooperated with China Pharmaceutical University.
Invested in research and development, and the Beimei shareholding platform was established
Sales exceeded 100 million RMB. Determined the development & in-licensing as the dual-drive strategy of the company.
Shenzhen Xieran Pharmaceutical Co., Ltd. was wholly-owned and renamed Shenzhen Beimei Pharmaceutical Co., Ltd.
Acquired 9 medicine approvals of Haibin Pharmaceutical Factory, and completed technology transfer and GMP certification of new workshops, completed marketing.
Establishment of the company